Stocks worldwide did not move significantly in the wake of Friday's tragic Paris attacks. Vincent Montemaggiore, portfolio manager for the Fidelity Overseas Fund (FOSFX) , said the lack of a meaningful market reaction demonstrates that international investors are taking a longer view.

"At the end of the day, we are long-term investors at Fidelity, and we really don't manage to the day-to-day," said Montemaggiore. "And over the long term we don't see much impact to business values."

The Fidelity Overseas Fund has risen 8% so far in 2015, according to fund-tracker Morningstar. The fund, which garners a full five stars from Morningstar, has outperformed 99% of its peers in its large blend category.

The price of a barrel of oil fell below $40 this week, despite increased worries about Middle East unrest as a result of the Paris tragedy. Montemaggiore said he is underweight the energy sector compared to his fund's benchmark, MSCI EAFE Index. Nevertheless, with oil prices having more upside than downside potential, he said he is slowly narrowing that deficit.

"I'm doing it more through industrials that have a lot of exposure to oil and gas, rather than be directly in the big integrated oils," said Montemaggiore.

He said he is also relatively underweight foreign financial stocks because they are still wrestling with quantitative easing programs in places like Europe and Japan.

"I see with the European banks a long period of declining net interest margins because this low rate environment makes it difficult for banks to make money and earn their cost of capital," said Montemaggiore, adding that fundamentals are also "under stress."

On the flip side, Montemaggiore is positive on the information technology space, although he admits that it is tough to pick winners when the advances are so rapid. As a result, he said he buys the "best-in-class IT services companies" that will come out on top whatever happens on a more granular level.

Finally, he is overweight health care in his fund, primarily owning European large-cap pharma names.  He said they are attractive from the perspectives of valuation, dividend yield and earnings growth. Still, he said he is gravitating toward medical technology companies due to both valuation and innovation.

More from Investing

When Is It 'Worth It' to Work With a Financial Advisor?

When Is It 'Worth It' to Work With a Financial Advisor?

Amazon, Microsoft and Google Face Backlash over ICE, Military Deals

Amazon, Microsoft and Google Face Backlash over ICE, Military Deals

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says